Attached files
| file | filename |
|---|---|
| EX-99.1 - NOVAVAX INC | v205665_ex99-1.htm |
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported) December 13, 2010
NOVAVAX,
INC.
(Exact
name of Registrant as specified in its charter)
|
Delaware
|
0-26770
|
22-2816046
|
||
|
(State
or other jurisdiction of incorporation or organization)
|
(Commission
File Number)
|
(I.R.S.
Employer Identification No.)
|
|
9920
Belward Campus Drive
Rockville,
Maryland
|
20850
|
|
|
(Address
of principal executive offices)
|
(Zip
Code)
|
|
Registrant’s
telephone number, including area code:
|
(240)
268-2000
|
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2.
below):
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item 5.02(b) Director
Resignation.
On
December 13, 20101, John Lambert resigned as a director of Novavax, Inc. (the
“Company”). Mr. Lambert did not serve on any committee of the Board of Directors
of the Company at the time of his resignation. Mr.
Lambert’s resignation followed his replacement as Executive Chairman
and the
formation of a Flu and New Products Committee of the Board of Directors of which
Mr. Lambert was not a member. Mr. Lambert purports that his resignation was
prompted by disagreements with the Company that are outlined in Mr. Lambert’s
letter of resignation, which is attached as an exhibit to this Current Report on
Form 8-K. The Board of Directors of the Company disagrees with Mr. Lambert’s
characterization of the circumstances surrounding his resignation and his
recitation of the facts, and the Company refers investors to the Company’s
Current Report on Form 8-K, dated December 2, for background. In light of Mr.
Lambert’s resignation, the Board of Directors has elected to disband the Flu and
New Products Committee.
Item 9.01. Financial
Statements and Exhibits.
(d) Exhibits
Exhibits
|
|
99.1
|
Copy of John Lambert letter of
resignation
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized
|
Novavax, Inc.
(Registrant)
|
||||
|
December 16,
2010
|
By:
|
/s/ John A. Herrmann III | ||
|
Name:
|
John A. Herrmann III | |||
|
Title:
|
Executive Director, Legal Affairs and Corporate Secretary | |||
2